A first-in-class product for the clearance of high-risk human papillomaviruses
Active Project Grant Awarded Last action
- Award ID
- R44AI188623
- Recipient
-
Dare Bioscience, Inc. UEI UC4EFLZHANH4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,000,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 97% complete
- Place of performance
- San Diego, CA 92122, USA
Award details come from USAspending.gov.
Description
- Abstract
- Daré bioscience is developing dare-HPV, an innovative anti-viral vaginal insert to address the health threat posed by persistent high-risk human papillomaviruses (HR-HPV) infections, which are associated with cervical cancers. With a lack of FDA-approved treatments for persistent HR-HPV infections, this novel therapy combines two antiretroviral drugs, lopinavir and ritonavir, targeting the viral lifecycle and restoring normal cellular growth. A clinical proof-of-concept study showed promising results, with a significant proportion of women experiencing HR-HPV viral clearance 12 weeks after a 14-day treatment. The proposed sbir phase II studies are focused on achieving three main objectives to ensure dare-HPV's safety before submitting an IND application. First, they aim to optimize and validate analytical assays for measuring the active pharmaceutical ingredients presence in both blood and cervical samples. Second, they will conduct comprehensive intravaginal safety and toxicity studies in a relevant biological model, female sheep. These studies are designed to confirm the absence of clinical pathology and define the pharmacokinetic parameters in the blood and cervical tissue after administration. Third, they will evaluate the potential for dare-HPV dermal hypersensitivity and evaluate the impact of dare-HPV on condom integrity. Upon successful completion of these studies, daré bioscience intends to file for IND status using the 505(B)(2) pathway, with kaletra® as the reference drug.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Original award | $1,000,000 |
Quick answers
Who received award R44AI188623?
R44AI188623 was awarded to Dare Bioscience, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 17, 2024.
How much is award R44AI188623 worth?
$3,000,000 has been obligated on R44AI188623.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award